

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and QMED CME, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of 17.50 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 17.50 ANCC contact hours.

Nurse Practitioners

AANP Credit Designation Statement

This education activity has been approved by the American Association of Nurse Practitioners for up to 17.50 contact hours of accredited education.

You must request your certificate within 45 days of the activity to meet the deadline for submission to AANP. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurse Pharmacology

This activity is eligible for up to 5.00 pharmacotherapeutic hours. Please note onsite agenda for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board.

Objectives - After Attending This Program You Should Be Able To

1. Apply evidence-based diagnostic tools — including noninvasive imaging, molecular testing, and phototherapy modalities— to improve skin cancer detection, risk stratification, and treatment planning across dermatologic conditions.
2. Differentiate the multifactorial pathogenesis of acne vulgaris and select appropriate prescription, emerging, and OTC therapies to construct individualized, stepwise acne management plans.
3. Evaluate the mechanisms, efficacy, and safety profiles of current and emerging systemic therapies — including biologics and JAK inhibitors — for atopic dermatitis across pediatric and adult populations.
4. Identify the immunologic and follicular mechanisms underlying hidradenitis suppurativa and develop individualized treatment plans incorporating approved biologic and small molecule agents.
5. Differentiate clinical subtypes of psoriatic disease — including pustular variants and psoriatic arthritis — and integrate current and emerging systemic therapies, including novel GLP-1 pathways, into comprehensive management.
6. Apply targeted and non-steroidal therapeutic strategies for vitiligo, urticaria, and chronic hand eczema using current clinical evidence and emerging treatment options.
7. Diagnose and manage common hair disorders — including alopecia areata, non-inflammatory hair loss, and scalp disease — using structured clinical evaluation, trichoscopy, and evidence-based medical and procedural therapies.
8. Compare the pharmacologic properties, anatomical considerations, and injection techniques for neurotoxins and dermal fillers across commonly and advanced-treated facial areas to achieve safe, balanced aesthetic outcomes.

9. Evaluate energy-based devices, thread lifting, submental fat reduction, and hair restoration modalities to guide appropriate patient selection, treatment planning, and complication management in aesthetic practice.
10. Develop operational and clinical strategies for building a successful aesthetic medicine practice, including workflow integration, patient selection, risk mitigation, and market trend adoption.